Measles, Mumps, Rubella
Conditions
Keywords
Mumps, Immunity, Vaccine, Mumps antibodies, Mumps immunity
Brief summary
This study will lay the foundation for determining the underlying reasons for lack of immunity to mumps that led to the 2006 mumps outbreak on college campuses in the Mid West, and it will assess the potential for similar outbreaks of measles and rubella. A total of 70 to 80 college students (age 18 to 22) on the Emory campus (or nearby college campuses or the community) will be assessed for antibodies to measles, mumps or rubella by drawing a one-time blood sample. Their medical records will be verified for documentation of immunization with MMR vaccine prior to enrollment in the study. If a study volunteer is found to not have MMR immunity, they will be offered an MMR-II vaccine. For this group, additional blood specimens will be obtained.
Detailed description
No additional description needed.
Interventions
BIOLOGICALMMR vaccine
People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
Sponsors
Merck Sharp & Dohme LLC
Sri Edupuganti, MD MPH
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 24 Years
Healthy volunteers
Yes
Inclusion criteria
* Ability and willing to provide an informed consent * Documented receipt of MMR-II vaccination in childhood * Not pregnant
Exclusion criteria
* No history of HIV infection. * Immunocompromised health status due to HIV infection, cancer, diabetes, liver, lung or kidney diseases, autoimmune diseases, history of splenectomy. * Use of immunosuppressive medications within last 2 to 3 months (oral or parenteral corticosteroids or cytotoxic medications) * Medical conditions that require the use of immunosuppressive medications * Received blood or blood products within the last 30 days * Any vaccines received in the last 30 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Levels of mumps antibody and levels of memory B and T cell responses | Day 1 for all participants except for those who receive MMR vaccine, there will be additional outcome measures on Day 0, 7, 14 and 28 post-vaccination. | Cross sectional measurement of antibodies to mumps. measles or rubella |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determine proportion of college-aged students who are seronegative for mumps | outcome measurement on Day 1 | Cross-sectional measurement of antibodies to mumps, measles and rubella |
Countries
United States
Outcome results
None listed